466 related articles for article (PubMed ID: 22214781)
1. Amyloid-β oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimer's disease.
Santos AN; Ewers M; Minthon L; Simm A; Silber RE; Blennow K; Prvulovic D; Hansson O; Hampel H
J Alzheimers Dis; 2012; 29(1):171-6. PubMed ID: 22214781
[TBL] [Abstract][Full Text] [Related]
2. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
[TBL] [Abstract][Full Text] [Related]
3. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.
Sundelöf J; Sundström J; Hansson O; Eriksdotter-Jönhagen M; Giedraitis V; Larsson A; Degerman-Gunnarsson M; Ingelsson M; Minthon L; Blennow K; Kilander L; Basun H; Lannfelt L
J Alzheimers Dis; 2010; 21(2):471-8. PubMed ID: 20555147
[TBL] [Abstract][Full Text] [Related]
4. The load of amyloid-β oligomers is decreased in the cerebrospinal fluid of Alzheimer's disease patients.
Sancesario GM; Cencioni MT; Esposito Z; Borsellino G; Nuccetelli M; Martorana A; Battistini L; Sorge R; Spalletta G; Ferrazzoli D; Bernardi G; Bernardini S; Sancesario G
J Alzheimers Dis; 2012; 31(4):865-78. PubMed ID: 22717612
[TBL] [Abstract][Full Text] [Related]
5. Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects.
Maccioni RB; Lavados M; Guillón M; Mujica C; Bosch R; Farías G; Fuentes P
Neurobiol Aging; 2006 Feb; 27(2):237-44. PubMed ID: 16399209
[TBL] [Abstract][Full Text] [Related]
6. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.
Hampel H; Teipel SJ; Fuchsberger T; Andreasen N; Wiltfang J; Otto M; Shen Y; Dodel R; Du Y; Farlow M; Möller HJ; Blennow K; Buerger K
Mol Psychiatry; 2004 Jul; 9(7):705-10. PubMed ID: 14699432
[TBL] [Abstract][Full Text] [Related]
7. High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients.
Fukumoto H; Tokuda T; Kasai T; Ishigami N; Hidaka H; Kondo M; Allsop D; Nakagawa M
FASEB J; 2010 Aug; 24(8):2716-26. PubMed ID: 20339023
[TBL] [Abstract][Full Text] [Related]
8. CSF-tau and CSF-Abeta(1-42) in posterior cortical atrophy.
Baumann TP; Duyar H; Sollberger M; Kuhle J; Regeniter A; Gomez-Mancilla B; Schmidtke K; Monsch AU
Dement Geriatr Cogn Disord; 2010; 29(6):530-3. PubMed ID: 20606434
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid biomarkers and memory present distinct associations along the continuum from healthy subjects to AD patients.
Rami L; Fortea J; Bosch B; Solé-Padullés C; Lladó A; Iranzo A; Sánchez-Valle R; Molinuevo JL
J Alzheimers Dis; 2011; 23(2):319-26. PubMed ID: 21098971
[TBL] [Abstract][Full Text] [Related]
10. BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology.
Mulder SD; van der Flier WM; Verheijen JH; Mulder C; Scheltens P; Blankenstein MA; Hack CE; Veerhuis R
J Alzheimers Dis; 2010; 20(1):253-60. PubMed ID: 20164582
[TBL] [Abstract][Full Text] [Related]
11. Amyloid-β oligomers relate to cognitive decline in Alzheimer's disease.
Jongbloed W; Bruggink KA; Kester MI; Visser PJ; Scheltens P; Blankenstein MA; Verbeek MM; Teunissen CE; Veerhuis R
J Alzheimers Dis; 2015; 45(1):35-43. PubMed ID: 25547634
[TBL] [Abstract][Full Text] [Related]
12. CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease.
Chiasserini D; Parnetti L; Andreasson U; Zetterberg H; Giannandrea D; Calabresi P; Blennow K
J Alzheimers Dis; 2010; 22(4):1281-8. PubMed ID: 20930282
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid biomarkers for Alzheimer’s disease: diagnostic performance in a homogeneous mono-center population.
Johansson P; Mattsson N; Hansson O; Wallin A; Johansson JO; Andreasson U; Zetterberg H; Blennow K; Svensson J
J Alzheimers Dis; 2011; 24(3):537-46. PubMed ID: 21297262
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.
Fagan AM; Roe CM; Xiong C; Mintun MA; Morris JC; Holtzman DM
Arch Neurol; 2007 Mar; 64(3):343-9. PubMed ID: 17210801
[TBL] [Abstract][Full Text] [Related]
15. Oligomerization partially explains the lowering of Abeta42 in Alzheimer's disease cerebrospinal fluid.
Englund H; Degerman Gunnarsson M; Brundin RM; Hedlund M; Kilander L; Lannfelt L; Pettersson FE
Neurodegener Dis; 2009; 6(4):139-47. PubMed ID: 19521063
[TBL] [Abstract][Full Text] [Related]
16. The neurofilament heavy chain (NfH) in the cerebrospinal fluid diagnosis of Alzheimer's disease.
Brettschneider J; Petzold A; Schottle D; Claus A; Riepe M; Tumani H
Dement Geriatr Cogn Disord; 2006; 21(5-6):291-5. PubMed ID: 16484807
[TBL] [Abstract][Full Text] [Related]
17. Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias.
Bibl M; Mollenhauer B; Lewczuk P; Esselmann H; Wolf S; Trenkwalder C; Otto M; Stiens G; Rüther E; Kornhuber J; Wiltfang J
Mol Psychiatry; 2007 Jul; 12(7):671-80. PubMed ID: 17339876
[TBL] [Abstract][Full Text] [Related]
18. CSF amyloid-β peptides in neuropathologically diagnosed dementia with Lewy bodies and Alzheimer's disease.
Mollenhauer B; Esselmann H; Trenkwalder C; Schulz-Schaeffer W; Kretzschmar H; Otto M; Wiltfang J; Bibl M
J Alzheimers Dis; 2011; 24(2):383-91. PubMed ID: 21297274
[TBL] [Abstract][Full Text] [Related]
19. CSF biomarkers predict rate of cognitive decline in Alzheimer disease.
Kester MI; van der Vlies AE; Blankenstein MA; Pijnenburg YA; van Elk EJ; Scheltens P; van der Flier WM
Neurology; 2009 Oct; 73(17):1353-8. PubMed ID: 19858456
[TBL] [Abstract][Full Text] [Related]
20. The amyloid-β oligomer count in cerebrospinal fluid is a biomarker for Alzheimer's disease.
Wang-Dietrich L; Funke SA; Kühbach K; Wang K; Besmehn A; Willbold S; Cinar Y; Bannach O; Birkmann E; Willbold D
J Alzheimers Dis; 2013; 34(4):985-94. PubMed ID: 23313925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]